CORE--NEPHROLITHIASIS PATIENTS AND PURIFICATION OF URINARY PROTEIN INHIBITORS

核心--肾结石患者和尿蛋白抑制剂的纯化

• 批准号: 3754727
• 负责人: FREDRIC L COE
• 金额: --
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3754727
• 关键词: biomedical facility; human subject; inhibitor /antagonist; nephrolithiasis; patient /disease registry; urine

This core maintains our kidney stone patient data base. From the data base, the Core identifies appropriate patients for protocols in Projects 1, 3 and 4. Patients are contacted, and recruited into protocols. Where necessary, the Core establishes informed consent. For protocols involving 24 hour urine samples, the Core obtains the samples. From human urine samples and samples from the IH rats (Project 2, Core A), the Core prepares whole urine proteins and isolated nephrocalcin, Tamm Horsfall protein and Uropontin for use in Projects 2, 3, and 4.

该核心维护我们的肾结石患者数据库。从数据中 基础，核心确定项目方案的适当患者 1、3和4。与患者联系，并招募到方案中。在哪里 有必要的核心建立知情同意。用于涉及的协议 24小时尿液样品，核心获得样品。来自人类尿液 来自IH大鼠的样品和样品（项目2，核心A），核心 准备整个尿液蛋白和孤立的肾红细胞素，Tamm Horsfall 用于项目2、3和4的蛋白质和尿叉素。